STRO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.8M
-32.3%
14.5M
+24.7%
11.6M
+20.2%
9.7M
-84.8%
63.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.8M
-32.3%
14.5M
+24.7%
11.6M
+20.2%
9.7M
-84.8%
63.7M
Operating Expenses
39.7M
-10.1%
44.2M
-11.1%
49.7M
-14.5%
58.2M
-13.3%
67.1M
R&D
31.7M
-13.3%
36.6M
-0.2%
36.6M
-8.1%
39.9M
+4.0%
38.3M
SG&A
7.8M
+3.3%
7.6M
-12.4%
8.7M
-0.9%
8.7M
-15.5%
10.3M
Operating Income
-29888000
-0.8%
-29656000
+22.1%
-38049000
+21.5%
-48459000
-1348.7%
-3345000
EBITDA
-28425000
-0.3%
-28336000
+11.5%
-32033000
+13.4%
-37001000
-317.9%
17.0M
Net Income
-38533000
-0.1%
-38484000
+17.7%
-46762000
+17.8%
-56857000
-394.5%
-11499000
EPS (Basic)
$-2.33
+20.7%
$-2.94
$-6.70
-396.3%
$-1.35
EPS (Diluted)
$-2.33
+20.7%
$-2.94
$-6.70
-396.3%
$-1.35
Shares (Diluted)
16.6M
+26.7%
13.1M
8.5M
-0.3%
8.5M
Sutro Biopharma (STRO) — Financials